おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
PolyProx
company
About
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
- 1 - 10
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- £3.40M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
£3.40M
PolyProx has raised a total of
£3.40M
in funding over 2 rounds. Their latest funding was raised on
Apr 30, 2019 from a Seed round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 30, 2019 | Seed | £3.40M | 1 |
Cambridge Innovation Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
PolyProx is funded by 1 investors.
Cambridge Innovation Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Cambridge Innovation Capital
|
Yes | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
